| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/27/2009 | CN100490815C Cardiac and cerebral vascular disease treating medicinal composition |
| 05/27/2009 | CN100490810C Flashmelt oral dosage formulation |
| 05/27/2009 | CN100490801C Ginkgolide B dropping pill and its preparing method |
| 05/27/2009 | CN100490795C Red sage root salvianolic acid A injection formulation for treating cardiovascular diseases and preparation process thereof |
| 05/27/2009 | CN100490791C Compositions and methods to treat neovascularization and disease associated with thereof |
| 05/27/2009 | CN100490787C Capsule for treating heart palpitation |
| 05/27/2009 | CN100490786C Chinese traditional medicine preparation for treating heart disease and preparation method |
| 05/27/2009 | CN100490785C Freeze-dried 'Shengmai' powder for injection and its preparing process |
| 05/27/2009 | CN100490783C No-sugar Mailuoning granule and its preparing process and quality control method |
| 05/26/2009 | US7538215 Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 05/26/2009 | US7538133 Benzimidazole derivatives, their production and use |
| 05/26/2009 | US7538118 6-aminomorphinane derivatives, method for production and use thereof |
| 05/26/2009 | US7538109 Quinoxalin-3-one derivatives as orexin receptor antagonists |
| 05/26/2009 | US7538091 D-retro-inverso amino acid sequence transporter peptide conjugated to nucleic acid biological effector; translocation across the membrane of pancreatic B-cells |
| 05/26/2009 | US7538089 Anti-inflammatory compounds and uses thereof |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | CA2497857C Novel p-selectin ligand protein |
| 05/26/2009 | CA2494165C Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 05/26/2009 | CA2474373C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists |
| 05/26/2009 | CA2459432C Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 05/26/2009 | CA2403630C Methods for inhibiting angiogenesis and tumor growth |
| 05/26/2009 | CA2367017C Inhibitors of impdh enzyme |
| 05/26/2009 | CA2355077C Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 05/26/2009 | CA2344058C Diaminopropionic acid derivatives |
| 05/26/2009 | CA2334773C Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use |
| 05/26/2009 | CA2298523C Therapeutic process for inhibiting nf-.kappa.b |
| 05/26/2009 | CA2254420C Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 05/26/2009 | CA2225903C Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use |
| 05/26/2009 | CA2091102C Microsomal triglyceride transfer protein |
| 05/22/2009 | WO2009065131A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| 05/22/2009 | WO2009065130A2 Modified release formulations of diltiazem |
| 05/22/2009 | WO2009064479A1 Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
| 05/22/2009 | WO2009064431A1 Methods of use |
| 05/22/2009 | WO2009064023A1 Skin moisturizer, blood circulation promoter, and external preparations for the skin containing the skin moisturizer and the blood circulation promoter |
| 05/22/2009 | WO2009064004A1 Citrulline-containing drink |
| 05/22/2009 | WO2009063995A1 Diagnosis and treatment of arteriosclerosis |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/22/2009 | WO2009063990A1 Benzazepinone compound |
| 05/22/2009 | WO2009063931A1 Method for evaluation of blood circulation-promoting activity, method for screening of blood circulation-promoting substance, and blood circulation promoter |
| 05/22/2009 | WO2009063821A1 Heteroaryloxy quinazoline derivative |
| 05/22/2009 | WO2009063301A1 Sphingosine- 1- phosphate (s1p) receptor compounds |
| 05/22/2009 | WO2009062914A2 Blood pressure lowering combination comprising ipp and/or vpp |
| 05/22/2009 | WO2009062910A1 Composition for moderating triglyceride and cholesterol levels |
| 05/22/2009 | WO2009062683A1 C-19 steroids for therapeutic uses |
| 05/22/2009 | WO2009062662A1 Pharmaceutical and nutraceutical compositions based on menaquinols |
| 05/22/2009 | WO2009062605A1 Trisubstituted furopyrimidines and the use thereof as activators of the ip receptor |
| 05/22/2009 | WO2009062402A1 Quinazolinone derivatives, the preparation methods and uses thereof |
| 05/22/2009 | WO2009062371A1 Carbamate derivatives, and the use as medicament |
| 05/22/2009 | WO2009062258A1 N-containing heterocyclic compounds |
| 05/22/2009 | WO2009043507A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009043468A3 Use of corticotropin-releasing factor as a therapeutic agent |
| 05/22/2009 | WO2009040087A3 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 05/22/2009 | WO2009040073A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040032A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040025A3 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 05/22/2009 | WO2009039969A3 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 05/22/2009 | WO2009033822A3 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 05/22/2009 | WO2009033812A3 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 05/22/2009 | WO2009033800A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033771A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033736A3 Use of met-enkephalin as a therapeutic agent |
| 05/22/2009 | WO2009033735A3 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 05/22/2009 | WO2009033669A3 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent |
| 05/22/2009 | WO2008145375A3 Kit of nutritional compositions for infants with fat and carbohydrate content adapted to the particular stage of development |
| 05/22/2009 | CA2706557A1 Skin moisturizer, blood circulation promoter, and external preparations for the skin containing the skin moisturizer and the blood circulation promoter |
| 05/22/2009 | CA2706556A1 Citrulline-containing beverage |
| 05/22/2009 | CA2705947A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| 05/22/2009 | CA2705916A1 Benzazepinone compound |
| 05/22/2009 | CA2705862A1 Compositions and method for manipulating pim-1 activity in circulatory system cells |
| 05/22/2009 | CA2705689A1 Trisubstituted furopyrimidines and the use thereof as activators of the ip receptor |
| 05/22/2009 | CA2705370A1 Heteroaryloxy quinazoline derivatives |
| 05/22/2009 | CA2703600A1 N-containing heterocyclic compounds |
| 05/21/2009 | US20090131946 Devices and Methods for the Restoration of a Spinal Disc |
| 05/21/2009 | US20090131668 4-oxo-4,6,7,8-Tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds |
| 05/21/2009 | US20090131513 Anti-inflammatory modalities |
| 05/21/2009 | US20090131497 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 05/21/2009 | US20090131496 Pyrazolone derivative emulsion formulations |
| 05/21/2009 | US20090131482 Methyl-benzimidazole derivatives |
| 05/21/2009 | US20090131459 2-Thioxanthine Derivatives Acting as MPO-Inhibitors |
| 05/21/2009 | US20090131456 Caspase inhibitors and uses thereof |
| 05/21/2009 | US20090131429 Pharmaceutical compounds |
| 05/21/2009 | US20090131418 Spiroazacyclic compounds as monoamine receptor modulators |
| 05/21/2009 | US20090131409 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| 05/21/2009 | US20090131404 Combinations |
| 05/21/2009 | US20090131396 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
| 05/21/2009 | US20090131395 Biphenylazetidinone cholesterol absorption inhibitors |
| 05/21/2009 | US20090131384 Compounds and methods for treatment of disorders associated with er stress |
| 05/21/2009 | US20090131379 Vitamin d receptor activators and methods of making |
| 05/21/2009 | US20090131376 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same |
| 05/21/2009 | US20090131350 Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor |
| 05/21/2009 | US20090131331 Novel Nutraceutical Compositions |
| 05/21/2009 | US20090131321 Method of reducing injury to mammalian cells |
| 05/21/2009 | US20090131314 Thrombospondin-1 Derived Peptides and Treatment Methods |
| 05/21/2009 | US20090130681 21132, a Human G-protein coupled receptor family member and uses therefor |
| 05/21/2009 | US20090130229 Antitumor uses of compound |
| 05/21/2009 | US20090130218 Association of Oleaginous Substance With a Mixture of at Least Two Cyclodextrins |
| 05/21/2009 | US20090130208 Modified release niacin formulations |
| 05/21/2009 | US20090130126 Dna expression vectors |
| 05/21/2009 | US20090130121 Synthetic Peptide Copolymers for Treatment and Prevention of Cardiovascular Disorders |
| 05/21/2009 | US20090130100 Methods of using humanized antibodies and compositions for binding sphingosine-1-phosphate |